Navigation Links
Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture
Date:6/30/2011

reated patient had a serious adverse event of a motor vehicle accident, which was considered unrelated to drug.
  • The adverse event profile of XIAFLEX treated joints through three years follow-up revealed no new long-term adverse events.
  • Of the 74 serious adverse events reported through three years of follow-up, none were considered related to XIAFLEX and none occurred in the treated finger.

    • "While I am very impressed with the three year recurrence rate of 35% using a 20 degree change to define recurrence, the surgical literature has often defined recurrence as a 30 degree change.  Using this definition, XIAFLEX demonstrates an even lower 22% recurrence rate at three years,” said Dr. Vincent Hentz, Professor Emeritus, Surgery - Plastic/Recon Surgery, Stanford Medical School.  “With this longer term data, I believe that treatment with XIAFLEX of Dupuytren’s patients’ palpable cords can provide durable outcomes with a very acceptable rate of recurrence in the majority of patients.”

    Recurrence with XIAFLEX as defined by greater than or equal to 30 degrees standard used in surgical literatureAlthough there is no standard methodology to measure recurrence, the literature(2,3,4), on surgical treatment does reference a definition of recurrence as a 30 degree worsening of contracture following an intervention.  XIAFLEX recurrence was defined in the AUX-CC-860 clinical study as a 20 degree change in the presence of a palpable cord.  In order to evaluate within the context of the existing surgical literature, the three year XIAFLEX data was examined using a criterion referenced in the literature.  Specifically, for this post hoc analysis, the definition of recurrence was (a) a joint contracture that was successfully treated (had previously achieved a reduction in contracture to five degrees or less at the Day 30 evaluation after the last injection of XIAFLEX) that subsequently increases
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
    3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
    4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
    5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
    6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
    7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
    8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
    9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
    11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
    (Date:6/18/2013)... 18, 2013  Actavis, Inc. (NYSE: ACT ) ... the U.S. Securities and Exchange Commission (SEC) a registration statement ... Warner Chilcott plc (NASDAQ: WCRX ), ... Warner Chilcott (the "Form S-4"). As previously ... have entered into a definitive agreement pursuant to which ...
    (Date:6/18/2013)...  Recent regulatory and budget challenges have made it ... large pharmaceutical companies to effectively educate doctors and other ... their new products. With the pressure to reduce budgets ... these "Med Ed" groups find practical, economical ... the changes that are transforming the Medical Education area ...
    Breaking Medicine Technology:Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2
    ... May 5, 2011 Novartis Pharmaceuticals Corporation ("Novartis") announced ... approved Afinitor® (everolimus) tablets for the treatment of progressive ... unresectable, locally advanced or metastatic disease(4). This marks the ... in the US in nearly 30 years(5). ...
    ... FRANCISCO, May 5, 2011 Cardiac Network, Inc. (Other OTC: ... a 1-for-750 reverse stock split (the "Reverse Stock Split"). The ... business and trading on May 6, 2011 (the "Effective Date"). ... changed from "CNWI" to "CNWID" for approximately 20 business days, ...
    Cached Medicine Technology:Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 2Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 3Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 4Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 5Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 6Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 7Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 8Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 9Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 10Cardiac Network Announces Reverse Stock Split 2
    (Date:6/18/2013)... Exposed Skin Care has finally been released after much anticipation ... finally achieve the clear, beautiful skin they have always dreamed ... system combines the power of science and nature to both ... , After a quick review of Exposed Skin ... most effective available on the market to cure acne both ...
    (Date:6/18/2013)... Recent studies linking bullying and depression, coupled with ... people, led the Centers for Disease Control and ... focus on these issues. This panel synthesized the ... involvement in bullying and suicide-related behaviors. Three themes ... public health problem, with widespread and often harmful ...
    (Date:6/18/2013)... An apple a day might really keep ... with breast cancer, she chose a different method for ... Myself Cancer, I Can Take It Away!: Alternatives Brought ... explains how changing her physical, mental and emotional diet ... made to feel fearful when diagnosed with a disease ...
    (Date:6/18/2013)... Cheap Concert Tickets has released additional inventories ... gets underway in July. Soccer fans can add code ... , The popularity and hype of soccer has ... the hype of the game triggered the sports-minded citizens of ... the veins of fans from the Caribbean. The adrenalin ...
    (Date:6/18/2013)... As obesity rates sky rocket in the United ... during childbirth comes as no shock. Forceps are surgical equipment ... she is unable to do so herself and although they ... rates of complication for both the mother and the baby. ... and child, forceps births add to the pressure of healthcare ...
    Breaking Medicine News(10 mins):Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:Bullying and suicide among youth is a public health problem 2Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 2Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 3Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2
    ... Mayo Clinic researchers have discovered that a chemical known ... for the effectiveness of tamoxifen in treating breast cancer, ... unexpected way. , Their study, being presented at the ... (CTRC-AACR) 31st annual San Antonio Breast Cancer Symposium, finds ...
    ... their lower back pain are better off than those who ... a University of Alberta study. , The study, done in ... cent improvement in pain and function levels for people with ... of resistance training using dumbbells, barbells and other load-bearing exercise ...
    ... Liverpool Associates in Tropical Health (LATH), a consulting arm ... a 10 million contract to manage a programme of ... initiative in Malawi. , Led by the National ... 5 year programme supported by the Wellcome Trust, the ...
    ... large proteomics study on the brains of newborn mice ... obstetric or pediatric medicine can have profound and long-term ... study, appearing in the December issue of Molecular ... the developing nervous system and reinforces the use of ...
    ... TCM Inc. of West Chester, PA ... named PCM Solutions, LLC, with Nalco Company ... the process industries, such as chemical and petrochemical manufacturing, ... paper manufacturing, food and beverage production, and various other ...
    ... Enhances First Global Medical Donations Map , ... The Partnership for Quality Medical Donations (PQMD) Mapping Tool, ... to information about the medical product donations being made ... to the world,s most vulnerable populations. Both the ...
    Cached Medicine News:Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 2Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 3Health News:LATH wins contract to boost health research capacity in Malawi 2Health News:The profound effects of numbing agents 2Health News:Haas TCM Inc. Forms PCM Solutions, LLC, a Joint Venture With Nalco Company, to Provide Chemical Management Services (CMS) to the Process Industries 2Health News:Global Mapping Tool Demonstrates Medical Donation Impact 2Health News:Global Mapping Tool Demonstrates Medical Donation Impact 3
    Hollow Copper Tube with Suction Port 16.5....
    Aluminum Stylette 16 with Adjustable Stop....
    Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
    Aluminum Stylette 16....
    Medicine Products: